We investigated the accuracy of various bleeding risk scores to estimate the bleeding risk in patients with acute myocardial infarction (AMI) managed with percutaneous coronary intervention (PCI) access via the radial artery.
I
n patients with acute myocardial infarction (AMI), bleeding is a common adverse effect post percutaneous coronary intervention (PCI) and is related to high morbidity and mortality. 1) Typically, patients with AMI could be prescribed various antithrombotic drugs, which could potentially result in different levels of bleeding, ranging from simple gastrointestinal bleeding to fatal intracranial hemorrhage. In fact, attaining a balance between bleeding and ischemic events is a clinical dilemma. Thus, bleeding risk stratification is imperative to manage patients with AMI.
In the AMI setting, commonly used bleeding risk scores (RS') currently include the following: (1) CRU-SADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines);
2) (2) ACTION (Acute Coronary Treatment and Intervention Outcomes Network); 3) and (3) the RS derived by Mehran, et al. from the combined dataset of the ACUITY-HORIZONS AMI (Acute Catheterization and Urgent Intervention Triage strategy and the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trials. 4) Although all the three RS systems comprise several overlapping clinical variables, CRUSADE was primarily developed to assist physicians to evaluate patients' baseline risk of major bleeding events during non-ST-elevation myocardial infarction (NSTEMI); however, the ACTION and ACUITY-HORIZONS models were used in patients with NSTEMI and ST-elevation myocardial infarction (STEMI). In addition, another RS for calculating the bleeding risk in patients with atrial fibrillation is HAS-BLED RS (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR [International normalized ratio], Elderly, Drugs/Alcohol con-CHEN, ET AL comitantly RS). 5) In patients with AMI, although consensus exists regarding the need for bleeding risk stratification, the best option as a clinical tool in the bleeding risk assessment among the available bleeding RS systems remains unclear. The 2017 ESC guidelines recommended transradial access in patients with AMI because it causes fewer bleeding complications; 6) however, most studies comprised PCI with transfemoral and transradial approaches. Reportedly, Asian patients possess a higher bleeding risk in acute coronary syndrome. 7) Nevertheless, none of these RS' has yet been validated in the transradial approach setting or implemented in the Chinese population for PCI.
Therefore, this study aimed to investigate the performance of the CRUSADE, ACTION, ACUITY-HORIZONS, and HAS-BLED RS systems to validate one of these systems as the most accurate and reliable quantitative clinical tool for predicting hemorrhagic complications and the overall mortality in patients with AMI.
Methods

Patient selection:
In this retrospective study, we enrolled all patients who were admitted with a final diagnosis of AMI, including STEMI or NSTEMI at discharge, between March 2010 and December 2013 to the Kaohsiung Chang Gung Memorial Hospital. We collected the demographic, clinical, and angiographic data and the data related to the management and in-hospital complications from the medical record database of our hospital. This retrospective chart review was approved by the Institutional Review Committee on Human Research of our institution (IRB: 103-5284B), and informed consent for PCI was obtained before the procedure from all patients. This study complies with the Declaration of Helsinki.
The diagnosis of AMI was made if the patient had new onset symptoms compatible with cardiac ischemia, cardiac biomarkers above the higher normal laboratory limit, and/or an electrocardiogram consistent with AMI change. Unless initial attempt had failed, all our patients underwent PCI via radial access. A loading dose of 300 mg of aspirin followed by 100 mg once daily, and 300 g of clopidogrel followed by 75 mg once daily, or 180 mg of ticagrelor followed by 90 mg twice daily were given. 8) The use of unfractionated heparin and low-molecularweight heparin was weight-adjusted as per standard recommendations. Exclusion criteria: The exclusion criteria in this study were as follows: patients with AMI precipitated by surgery, sepsis, or trauma and those who underwent PCI via access other than the radial artery. In our cohort, the numbers of patients using femoral approach, brachial approach, and ulnar approach were 45, 45, and 9 respectively. In addition, we excluded 10 other patients with missing data and incomplete variables for RS calculations. Lastly, we eliminated any patient with systemic hematological disorders, malignancy, or severe liver disease or those who refused PCI. Endpoints and definitions: In this study, we considered all hemorrhagic events that occurred within 30 days of the AMI onset. Accordingly, we collected the data on localization, imaging tests, admission, and nadir hemoglobin/ hematocrit levels from the laboratory database of our institution. In addition, we adopted Thrombolysis in Myocardial Infarction (TIMI) as the standard bleeding definition. 9) TIMI defined major bleeding events as those including intracranial hemorrhage, fatal bleeding (direct deathcausing bleeding within seven days), or clinically overt bleeding (including on imaging) related to a decline in hemoglobin of ! 5 g/dL. When necessary, computed tomography or magnetic resonance imaging of the brain was required to confirm intracranial hemorrhage. Furthermore, any clinically overt bleeding leading to a decline in hemoglobin of 3−5 g/dL was defined as a minor bleeding event. In this study, all bleeding events were described as a TIMI major or TIMI minor bleeding. Notably, TIMI serious bleeding was defined as TIMI major or TIMI minor bleeding. TIMI minimal bleeding was defined as any overt bleeding that did not meet the descriptions of TIMI major or minor bleeding or any clinically overt signs of hemorrhage associated with decline in hemoglobin of < 3 g/dL per day.
Cardiovascular death implied death due to a cardiogenic shock, sudden death, or cardiac arrest, recent AMI, life-threatening arrhythmias (ventricular tachycardia, ventricular fibrillation, or advanced atrioventricular node block), or congestive heart failure (HF). In addition, revascularization included target vessel revascularization and target lesion revascularization wherein target vessel revascularization was defined as any repeated PCI in the target vessel, and target lesion revascularization implied repeated PCI within the index procedure stent or 5-mm edge. Furthermore, major adverse cardiac events (MACEs) were termed as all-cause death, myocardial infarction (MI), and the requirement for repeated revascularization by redocoronary artery bypass graft or repeated PCI.
Statistical analysis:
We have presented continuous data as mean ± standard deviations and categorical data as counts (%). Using receiver operating characteristic (ROC) curves, we assessed the predictive validities of 30-day bleeding in various scoring systems. In addition, cstatistics were compared using the MedCalc statistical software (version 17.9.7; MedCalc Software, Mariakerke, Belgium). After the ROC curve analysis, we confirmed the best cut-off value to predict the 30-day bleeding rate at the points with the highest sum of sensitivity and specificity. Based on the best cut-off value in various outcomes, the Kaplan-Meier survival curve revealed the 30-day event-free survival curve for various cardiovascular outcomes, which we compared using the log-rank test. Furthermore, to predict 30-day bleeding and 30-day allcause mortality, we entered clinically pre-specified predictors with P < 0.1 in the univariate analysis into the multivariate regression analysis with a forward stepwise method. In this study, data are presented as the odds ratio (OR) and 95% confidence interval (CI), and we considered P < 0.05 to be statistically significant. Except for the c-statistics, we evaluated all other statistics using the software package SPSS version 21.0 (SPSS Inc., Chicago, IL, USA). 2.9%, respectively; moreover, the TIMI serious bleeding rate was 3.6% and the TIMI minimal bleeding rate was 11.6%. Most bleeding events originated from the gastrointestinal tract (88%), followed by vascular access site (0.3%, six patients) and intracranial hemorrhage (0.2%, three patients). Furthermore, the number of major adverse cardiac events, including all-cause death/MI/revascularization, in !30 days was 117 (7.1%). Discrimination ability of the RS': Figure 1 presents the area under the curve (AUC) of the four RS systems and their comparison. Overall, ACUITY-HORIZONS exhibited the highest AUC (c = 0.75), whereas HAS-BLED RS exhibited the lowest score (c = 0.676). When compared to ACUITY-HORIZONS, ACTION and CRUSADE may not show significant difference in the discrimination ability (P value of 0.55 and 0.27, respectively), but HAS-BLED RS, which has the lowest score, obtained a P value of 0.01. In addition, Table III summarizes the calibration and discrimination of the four RS systems. Table III demonstrates that the calibration of the ACUITY-HORIZONS, CRU-SADE, and ACTION models was remarkable in predicting the 30-day bleeding events in our study cohort. Furthermore, the three models also exhibited an adequate discriminatory capacity for major bleeding. HosmerLemeshow test P values of these three RS' were > 0.1. However, the HAS-BLED RS did not exhibit similar results and had a poor calibration and discrimination power. Because the ACUITY-HORIZONS RS model has the highest AUC, suggesting that this RS model has the best predictive power among the four RS systems, we further classified the patients into the following four groups: 4) (1) low risk, < 10; (2) moderate risk, 10-14; (3) high risk, 15-19; and (4) very high risk, >20. Figure 2 demonstrates the comparison between the percentages of predicted and observed 30-day TIMI serious bleeding incidents. Notably, the observed that the bleeding risk in each group of our patient cohort was similar to that in the predicted group accordingly. Besides, there was no statistical difference BLEEDING RISK MODEL FOR AMI WITH TRANSRADIAL PCI between the low and moderate groups in the observed patients (P = 0.66) to discriminate 30-day TIMI serious bleeding, but significant statistical differences were noted between the moderate versus high risk (P < 0.01) and the high versus very high risk (P < 0.01) groups. Thus, we chose not to use four risk groups but instead using the cut-off value of 17, which was found to be significant by c-statistics (sensitivity: 81.67%, specificity: 62.73%).
BLEEDING RISK MODEL FOR AMI WITH TRANSRADIAL PCI
Based on the sensitivity and specificity analysis, we used 17 in the ACUITY-HORIZONS RS model as the cut-off value to define the high and low bleeding risks. We observed that the best predictive value of TIMI serious bleeding and the highest sensitivity of ACUITY-HORIZONS are presented when the predictive value is > 17, which can also distinguish the differences among 30-day bleeding, all-cause death, 30-day CV death, and 30-day MACE (P < 0.01), although it cannot distinguish among 30-day stroke, 30-day MI, or 30-day revascularization ( Figures 3A-G) .
Predictors of bleeding outcome and mortality:
Using logistic regression analysis, we assessed clinical baseline variables (Table IV) as potential predictors of the 30-day TIMI serious bleeding after AMI. The multivariate analysis determined the factors related to the 30-day TIMI serious bleeding. In this study, the factor with the strongest association was the initial systolic blood pressure (SBP) < 90 mmHg (OR: 2.61; 95% CI, 1.19-5.72), followed by Killip class III and IV upon admission (OR: 2.49; 95% CI, 1.07-5.80), baseline hemoglobin < 10 g/dL (OR: 2.27; 95% CI, 1.14-4.34), ACUITY-HORIZON score > 17 (OR: 2.98; 95% CI, 1.18-7.49), and age (OR: 1.04; 95% CI, 1.01-1.07). Furthermore, we used the multivariate logistic regression analysis to predict the 30-day mortality (Table  V) . The multivariate analysis revealed that the factor that was highly associated with the 30-day mortality was recurrent MI within 30 days (OR: 24.19; 95% CI, 4.62-126.34), followed by TIMI major bleeding within 30 days 
Discussion
To the best of our knowledge, this is the first study to compare the predictive value in the four contemporary bleeding RS systems using an independent dataset of Chinese patients with AMI managed with all PCI access via the radial artery.
Comparison of RS:
This study attempted to assess the performance of CRUSADE, ACUITY-HORIZONS, AC-TION, and HAS-BLED RS in a Chinese cohort of transradial PCI-treated AMI using the definition of TIMI serious bleeding. The CRUSADE, ACTION, and ACUITY-HORIZONS scores presented good calibration and discrimination abilities in the Chinese population; however, the HAS-BLED model did not exhibit similar results. A comprehensive assessment revealed minor differences in the results, and a meta-analysis also suggested that ACTION, CRUSADE, and ACUITY-HORIZONS similarly performed while predicting the risk of bleeding in patients with AMI. 10) Initially, all these RS systems were developed in patient cohorts in whom the femoral approach was predominantly used, and none has been confirmed for the use with the radial approach, which now constitutes the recommended access site in coronary angiography and PCI for AMI. 6) In this study, we observed that the ACUITY-HORIZONS RS performed better than the CRUSADE and ACTION systems in terms of the predictive ability for 30-day major bleeding, although Abu-Assi, et al. reported the 14) However, different from the study of Liu, et al., our study cohort included both STEMI and NSTEMI patients. Compared with NSTEMI patients, STEMI patients generally have a lower prevalence of comorbidities and shorter hospital-associated delays. Besides, there are many differences between our study and Liu, et al.'s study about in-hospital management and vascular access site. 13) Thus, it resulted in different results. Indeed, it is reasonable that the ACUITY-HORIZONS score exhibited a better outcome in our study because, while the CRUSADE and ACTION RS systems were designed for predicting in-hospital bleeding rate alone, the ACUITY-HORIZONS score aims to predict the 30-day bleeding rate.
BLEEDING RISK MODEL FOR AMI WITH TRANSRADIAL PCI
Hsieh, et al., who reported that the HAS-BLED score exhibited a similar accuracy for the risk assessment as CRUSADE and ACUITY-HORIZONS in patients with NSTEMI, however we observed dissimilar results when it was applied to all patients with ACS. 15) Although the HAS-BLED score includes several factors different from the other three RS systems (an abnormal liver function test, alcohol use, NSAIDs use, and high INR), the presence of these four factors was found in < 1% of our patients. Of nine factors, only five were frequently observed in our patients with AMI; thus, based on this study, we do not recommend the use of the HAS-BLED score for predicting the 30-day bleeding rate in the AMI population owing to its lowest predictive value. The ACUITY-HORIZONS System: This study revealed that the ACUITY-HORIZONS score exhibited the best predictive value of the TIMI 30-day serious bleeding rate when it was > 17. In addition, we observed significant differences in all-cause death, CV death, and MACE in the groups with a score of !17 and > 17. As the score ! 17 implies a lower bleeding rate, it could illustrate the reasons for a lower risk of adverse events. Additionally, the ACUITY-HORIZONS System involves fewer and simpler factors than the other RS systems. Hence, it could be more efficient to categorize the patients into two groups using 17 as the cut-off value. Importantly, not only accurately predictive of bleeding events, it also differentiates the risk of 30-day mortality, CV death, and MACE. As shown in Tables IV and V , age, initial SBP !90 mmHg, and HF at admission are not only the risk factors of predicting 30-day bleeding but also risk factors of predicting 30-day mortality. Interestingly, anemia was a predictor for 30-day bleeding in our study. Anemia in the admission might imply patients are taking certain kinds of medication, and or have comorbidities of iron deficiency, bone marrow suppression, and renal dysfunction,. For acute coronary syndrome, patients with chronic kidney disease (CKD) are more anemic compared with non-CKD patients 16) and carry the risk of platelet dysfunction. Thus, it explains why anemia positively influence the 30-day bleeding. Indeed, both age and anemia are parameters of the ACUITY-HORIZONS RS system. Bleeding events after transradial PCI: In this study, the 30-day TIMI major bleeding rate was 0.7%, which was much lower than that in the ACUITY-HORIZONS cohort (1.7%).
4) The variations in the incidence could be attributed to differences in terms of study patients, transradial access, and use of medications, although our cohort tended to have lower body weight and higher prevalence rates for CKD, diabetes mellitus, and hypertension. In addition, the advancements in coronary invention technology and medication strategies, including the use of radial access site, further decline the bleeding rate. Thus, by adopting the radial approach, bleeding complications (femoral hematoma or retroperitoneal bleeding), which were often observed while using the femoral access site, substantially decrease. 17) Moreover, this study revealed that major bleeding of the vascular access site occurred only in 0.6% of all patients, which was notably lower than that previously reported (1.2%-8.4%). 18) In our study cohort, we used radial access in all patients and not thrombolysis therapy because of the high availability of PCI in our country. As bivalirudin was not available in our country, most patients in this study received heparin or enoxaparin for anticoagulation. 19) Furthermore, the use of glycoprotein IIbIIIa inhibitors was < 15% and only in patients with the conditions of heavy thrombosis or no reflow. These data imply that cautious prescription of antithrombotic treatment in acute stage of AMI and the use of transradial approach for PCI are important to reduce bleeding complications in this specific patient cohort. Clinical implications: In the era of developing tailored medical treatment, it is imperative for physicians to use various RS' suitable for different patient populations. Under the trend of using the radial access site, the bleeding rate has markedly declined; however, bleeding events (gastrointestinal bleeding or urogenital bleedings) remain prevalent and account for morbidity in patients. Apparently, RS models provide crucial information in terms of the dosage and regimen of antiplatelet or anticoagulant drugs required for administration. Based on our findings, we suggest using the ACUITY-HORIZONS score 17 as the cut-off point, which is indicative of higher bleeding and mortality rates. As most bleeding events are observed in the gastrointestinal tract, we suggest adding prophylactic proton pump inhibitors before or after the intervention. Nevertheless, further investigation might be warranted to focus on testing the ischemic and bleeding models in Chinese cohorts and to attempt developing a new risk prediction score for Chinese patients with AMI. Study limitations: This study has certain limitations. Firstly, this is a retrospective study, and we obtained all data from a single-center registry. Secondly, the enrolled patients received dual antiplatelet therapy with aspirin and ticagrelor/clopidogrel, although the latest guidelines suggest using aspirin with ticagrelor/prasugrel. Lastly, none of the patients in our study cohort received new oral anticoagulants. Clinically, it is a standard practice to administer dual antiplatelet therapy in combination with new oral anticoagulants, and our results are not applicable to these patients. Hence, further extensive prospective studies are warranted to overcome these limitations and assess the ap-plicability of our findings in broader perspectives.
Conclusions
This study demonstrates that ACUITY-HORIZON is the most reliable RS to predict the 30-day bleeding rate in patients with AMI undergoing transradial PCI, compared with other scoring systems. The ACUITY-HORIZONS score not only exhibits the best predictive value of the TIMI 30-day serious bleeding rate when > 17 but also presents considerable differences in all-cause death, CV death, and MACE. Overall, in the transradial scenario, bleeding and MI within 30 days positively correlate with the 30-day mortality.
